PRESS RELEASE published on 06/12/2025 at 22:42, 10 months 22 days ago Inside Information / Other news releases GeNeuro SA's French subsidiary GeNeuro Innovation SAS enters receivership proceedings amidst parent company's debt-restructuring efforts Autoimmune Diseases GeNeuro SA Neurodegenerative Diseases Debt-restructuring Receivership Proceedings
PRESS RELEASE published on 06/12/2025 at 22:42, 10 months 22 days ago Informations privilégiées / Autres communiqués GeNeuro annonce l’ouverture de la procédure de redressement judiciaire de sa filiale GeNeuro Innovation SAS. La société cherche à se restructurer pour surmonter ses difficultés financières Restructuration Difficultés Financières Redressement Judiciaire GeNeuro Sursis Concordataire
BRIEF published on 12/13/2024 at 12:02, 1 year 4 months ago Citigroup reduces its stake in GENEURO SA Euronext Paris Sale Of Shares Threshold Crossing GeNeuro SA Citigroup
BRIEF published on 12/13/2024 at 12:02, 1 year 4 months ago Citigroup réduit sa participation dans GENEURO SA Euronext Paris Franchissement De Seuil Vente D'actions GeNeuro SA Citigroup
PRESS RELEASE published on 12/13/2024 at 11:57, 1 year 4 months ago Franchissement de seuils Déclaration de franchissement de seuils de Citigroup Global Markets Limited concernant GENEURO SA publiée le 12 décembre 2024 Déclaration Franchissement De Seuils GeNeuro SA Citigroup Global Markets Limited
BRIEF published on 12/06/2024 at 18:35, 1 year 4 months ago GeNeuro dévoile son nouveau médicament de précision pour la SLA Médecine De Précision GeNeuro Traitement De La SLA GNK-301 ENVIRONNEMENT HERV-K
BRIEF published on 12/06/2024 at 18:35, 1 year 4 months ago GeNeuro's New Precision Medicine for ALS Unveiled Precision Medicine GeNeuro ALS Treatment GNK-301 HERV-K ENV
PRESS RELEASE published on 12/06/2024 at 18:30, 1 year 4 months ago Informations privilégiées / Autres communiqués Nouvelle approche de médecine de précision pour la SLA avec GNK-301 de GeNeuro présentée au 35e Symposium international sur la SLA/MMN Recherche Médecine De Précision GeNeuro SLA GNK-301
PRESS RELEASE published on 12/06/2024 at 18:30, 1 year 4 months ago Inside Information / Other news releases GeNeuro presents groundbreaking findings on precision medicine for ALS patients with GNK-301 at the 35th International Symposium on ALS/MND. Research highlights potential of targeting HERV-K ENV to transform ALS treatment Precision Medicine ALS GeNeuro GNK-301 HERV-K ENV
BRIEF published on 11/06/2024 at 09:48, 1 year 5 months ago Crossing of thresholds by Invus Public Equities in GENEURO SA Euronext Paris Capital Increase Crossing Thresholds GeNeuro SA Invus Public Equities
Published on 05/05/2026 at 01:59, 1 hour 55 minutes ago Tolmer Yields >100,000 g/t Silver Trial Gravity Concentrate
Published on 05/04/2026 at 23:55, 3 hours 59 minutes ago Avant Brands Announces Voting Results from Its 2026 Annual General and Special Meeting of Shareholders
Published on 05/04/2026 at 23:01, 4 hours 53 minutes ago Copper Road Announces Closing of Non-Brokered Private Placement
Published on 05/04/2026 at 23:00, 4 hours 54 minutes ago PJX Resources Adopting Semi-Annual Financial Reporting ("SAR")
Published on 05/04/2026 at 22:50, 5 hours 4 minutes ago IBC Advanced Alloys Announces Amendment of Existing Credit Facility
Published on 05/05/2026 at 02:42, 1 hour 11 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus secures strategic partnership with Boral to deliver one of Australia’s largest logistics precincts
Published on 05/05/2026 at 02:34, 1 hour 20 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: March 2026 quarter update and Macquarie Australia Conference Presentation
Published on 05/04/2026 at 21:05, 6 hours 49 minutes ago EQS-Adhoc: Brockhaus Technologies AG: Preliminary revenue for Q1 2026 of €47.9 million and adjusted EBITDA of €7.6 million; forecast for the continuing operations unchanged
Published on 05/04/2026 at 20:02, 7 hours 51 minutes ago EQS-Adhoc: Rheinmetall AG: Preliminary operating margin in line with market expectation; revenue below market expectation despite growth due to delays into Q2 – 2026 full-year forecast reaffirmed
Published on 05/04/2026 at 19:30, 8 hours 24 minutes ago Shareholders approve all proposals – Dr Annelise Lüscher Hämmerli and Urs Simeon elected to the Board of Directors
Published on 05/04/2026 at 20:57, 6 hours 56 minutes ago Covivio - Information on total number of voting rights and share capital
Published on 05/04/2026 at 20:57, 6 hours 56 minutes ago Covivio - Informations relatives au nombre total de droits de vote et d’actions composant le capital social
Published on 05/04/2026 at 20:06, 7 hours 48 minutes ago Avril 2026 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Published on 05/04/2026 at 19:05, 8 hours 49 minutes ago CP -Mise en œuvre d’un contrat de liquidité avec INVEST SECURITIES
Published on 05/04/2026 at 18:19, 9 hours 34 minutes ago Covivio Hotels - Informations relatives au nombre total de droits de vote et d’actions composant le capital social
